Lee Ainslie Viridian Therapeutics, Inc.\De Transaction History
Maverick Capital LTD
- $4.82 Billion
- Q3 2024
A detailed history of Lee Ainslie (Maverick Capital LTD) transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Maverick Capital LTD holds 1,997,153 shares of VRDN stock, worth $39.5 Million. This represents 0.94% of its overall portfolio holdings.
Number of Shares
1,997,153
Previous 3,307,945
39.63%
Holding current value
$39.5 Million
Previous $43 Million
5.57%
% of portfolio
0.94%
Previous 0.85%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
179Shares Held
76.8MCall Options Held
581KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$94.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.42MShares$87.5 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$76.8 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$74.2 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$68.2 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $789M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...